Hyloris Announces Start of Phase 2 Study of Miconazole-Domiphen Bromide Vaginal Cream in Vulvovaginal Candidiasis  

NEXT STORY
iOnctura to Share Preclinical Data on IOA-289 at SITC in November
PREV STORY
Using Machine Learning, Artificial Intelligence, and Real-World Data to Drive Launch Success for Rare Disease Therapies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease

author_avatar
NASDAQ Market News

CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline

author_avatar
NASDAQ Market News

Dental Prosthetics Market to Reach USD 9.71 Billion by 2026; Growing Cases of Dental Caries to Aid Expansion, states Fortune Business Insights™

author_avatar
NASDAQ Market News